Project Description

FORCE Webinar:

Hyalo Technologies
Dermatology and Plastic Surgery Nano-Sphere Platforms

RSVP:

Please join us to hear Dr. Shalabh Jain, Founder, Chairman and CEO of Hyalo Technologies, talk about his nano-sphere drug delivery platform and how it will revolutionize the $8.5B treatment opportunity for hypertrophic and keyloid scarring.

Date & Time:

May 21, 11:00 AM PDT
Webinar: Details provided upon RSVP approval

About the Event:

Every year over 200 million surgical incisions leave patients with permanent hypertrophic scars. In addition, keloids, a scar-like fibrous mass caused by excessive collagen growth, affects hundreds of thousands of people with darker skin pigmentation. Current treatment options for scar remediation have limited effectiveness and in a majority of cases scarring returns, often more pronounced than before the treatment.
Hyalo Technologies has developed an innovative treatment system that addresses the underlying cause of scarring. By using nanotechnology, they have created a timed-controlled release system that delivers a unique blend of active ingredients to degrade collagen networks, the foundation of both keloid and hypertrophic scar tissue.
Please join us online for a lively discussion of this innovative approach to scar treatment led by Dr. Shalabh Jain, Founder, Chairman and CEO of Hyalo Technologies. 

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.